Table 2.
Baseline characteristics and levels of cFAP in HC and IBD groups.
| Variable | HC ( n = 160) | IBD no surgery ( n = 152) | IBD surgery ( n = 120) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| n (%) | cFAP (ng mL−1) | p-value | n (%) | cFAP (ng mL−1) | p-value | n (%) | cFAP (ng mL−1) | p-value | |
| Gender | |||||||||
| Female | 100 (62.5) | 72.6 ± 30.1 | 0.09 | 60 (39.5) | 52.4 ± 24.6 | 0.23 | 47 (39.2) | 39.6 ± 17.7 | 0.58 |
| Male | 60 (37.5) | 83.1 ± 32.2 | 92 (60.5) | 57.8 ± 28.1 | 73 (60.8) | 43.7 ± 23.8 | |||
| Smoking | |||||||||
| Yes | 62 (38.8) | 74.9 ± 37.1 | 0.28 | 64 (42.1) | 55.5 ± 26.8 | 0.96 | 38 (31.7) | 38.7 ± 23.7 | 0.07 |
| No | 98 (61.2) | 77.6 ± 29.4 | 88 (57.9) | 55.8 ± 27.0 | 82 (68.3) | 43.6 ± 20.6 | |||
| Family history of IBD | |||||||||
| Yes | 17 (12.2) | 56.9 ± 21.9 | 0.94 | 16 (13.8) | 35.9 ± 16.5 | 0.25 | |||
| No | 122 (87.8) | 56.4 ± 27.1 | 100 (86.2) | 42.8 ± 21.3 | |||||
| Disease duration | |||||||||
| ≤ 10 years | 73 (51.8) | 56.5 ± 29.2 | 0.42 | 56 (50.5) | 42.0 ± 21.4 | 0.96 | |||
| >10 years | 68 (48.2) | 53.0 ± 22.2 | 55 (49.5) | 41.2 ± 18.7 | |||||
| Age at diagnosis | |||||||||
| A1, <16 years | 7 (4.9) | 51.0 ± 18.5 | 0.64 | 14 (12.1) | 41.9 ± 20.1 | 0.44 | |||
| A2, 17–40 years | 93 (64.6) | 53.8 ± 26.3 | 66 (56.9) | 40.3 ± 21.4 | |||||
| A3, >40 years | 44 (30.5) | 57.8 ± 26.1 | 36 (31) | 44.6 ± 20.3 | |||||
| Montreal location* | |||||||||
| L1, terminal ileum | 23 (27.4) | 51.6 ± 22.2 | 0.23 | 62 (66) | 41.0 ± 17.9 | 0.44 | |||
| L2, colon | 10 (11.9) | 66.9 ± 31.6 | 9 (9.6) | 51.3 ± 29.5 | |||||
| L3, ielocolon | 43 (51.2) | 51.9 ± 20.6 | 21 (22.3) | 40.3 ± 22.1 | |||||
| L4, upper gastrointestinal tract | 8 (9.5) | 50.0 ± 10.3 | 2 (2.1) | 55.6 ± 10.4 | |||||
| Montreal behavior* | |||||||||
| B1, non-stricturing non-penetrating | 36 (43.4) | 52.5 ± 23.5 | 0.71 | 5 (5.3) | 58.4 ± 37.4 | 0.67 | |||
| B2, stricturing | 35 (42.2) | 56.0 ± 20.9 | 43 (45.7) | 41.4 ± 17.8 | |||||
| B3, penetrating | 12 (14.4) | 50.8 ± 21.5 | 46 (49) | 41.1 ± 19.6 | |||||
| Perianal disease* | |||||||||
| Yes | 8 (10.3) | 34.2 ± 23.5 | 0.006 | 21 (20) | 36.1 ± 15.2 | 0.14 | |||
| No | 70 (89.7) | 61.8 ± 26.8 | 68 (80) | 43.6 ± 19.9 | |||||
| Montreal extent# | |||||||||
| E1, proctitis | 7 (12.5) | 39.4 ± 16.4 | 0.16 | 2 (9.5) | 45.5 ± 7.9 | 0.22 | |||
| E2, left-sided colitis | 19 (29.7) | 64.5 ± 37.1 | 1 (4.8) | 70.8 (± 0.0) | |||||
| E3, extensive colitis | 37 (57.8) | 59.5 ± 30.2 | 18 (85.7) | 34.8 ± 19.0 | |||||
| Medications | |||||||||
| Biological therapy | 119 (88.8) | 55.6 ± 24.8 | 0.71 | 32 (27.1) | 39.3 ± 20.5 | 0.01 | |||
| Other therapy | 9 (6.7) | 51.1 ± 27.7 | 50 (42.4) | 37.7 ± 20.1 | |||||
| None | 6 (4.5) | 62.1 ± 35.7 | 36 (30.5) | 49.3 ± 19.9 | |||||
cFap is expressed as mean ± SD.
*
Applicable to patients with CD only.
#
Applicable to patients with UC only.